Combination antiretroviral therapy and the risk of myocardial infarction Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group New England Journal of Medicine 349 (21), 1993-2003, 2003 | 2123 | 2003 |
Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis DA Machalek, M Poynten, F Jin, CK Fairley, A Farnsworth, SM Garland, ... The lancet oncology 13 (5), 487-500, 2012 | 1124 | 2012 |
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ... European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010 | 453 | 2010 |
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? E Fontas, F Van Leth, CA Sabin, N Friis-Møller, M Rickenbach, ... The Journal of infectious diseases 189 (6), 1056-1074, 2004 | 425 | 2004 |
Potential role for Interleukin‐28B genotype in treatment decision‐making in recent hepatitis C virus infection J Grebely, K Petoumenos, M Hellard, GV Matthews, V Suppiah, ... Hepatology 52 (4), 1216-1224, 2010 | 248 | 2010 |
Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study* K Petoumenos, S Worm, P Reiss, S De Wit, A d'Arminio Monforte, C Sabin, ... HIV medicine 12 (7), 412-421, 2011 | 212 | 2011 |
HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy D Lincoln, K Petoumenos, GJ Dore, ... HIV medicine 4 (3), 241-249, 2003 | 211 | 2003 |
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection GJ Dore, M Hellard, GV Matthews, J Grebely, PS Haber, K Petoumenos, ... Gastroenterology 138 (1), 123-135. e2, 2010 | 178 | 2010 |
Evaluation of self-collected samples in contrast to practitioner-collected samples for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis by … J Knox, SN Tabrizi, P Miller, K Petoumenos, M Law, S Chen, SM Garland Sexually transmitted diseases 29 (11), 647-654, 2002 | 165 | 2002 |
Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection J Grebely, ST Pham, GV Matthews, K Petoumenos, RA Bull, B Yeung, ... Hepatology 55 (4), 1058-1069, 2012 | 144 | 2012 |
Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment-Naive, HIV-1–Infected Individuals Commencing … A Winston, C Duncombe, PCK Li, JM Gill, SJ Kerr, R Puls, K Petoumenos, ... Clinical Infectious Diseases 50 (6), 920-929, 2010 | 115 | 2010 |
Plasma cystatin C is a predictor of renal dysfunction, acute‐on‐chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis D Markwardt, L Holdt, C Steib, A Benesic, F Bendtsen, M Bernardi, ... Hepatology 66 (4), 1232-1241, 2017 | 106 | 2017 |
Long-term survival in HIV positive patients with up to 15 years of antiretroviral therapy H McManus, CC O'Connor, M Boyd, J Broom, D Russell, K Watson, ... PloS one 7 (11), e48839, 2012 | 100 | 2012 |
Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy CJ Miller, JV Baker, AM Bormann, KM Erlandson, K Huppler Hullsiek, ... PloS one 9 (4), e95061, 2014 | 95 | 2014 |
HCV reinfection incidence among individuals treated for recent infection M Martinello, J Grebely, K Petoumenos, E Gane, M Hellard, D Shaw, ... Journal of viral hepatitis 24 (5), 359-370, 2017 | 93 | 2017 |
Plasma interferon‐gamma‐inducible protein‐10 (IP‐10) levels during acute hepatitis C virus infection J Grebely, JJ Feld, T Applegate, GV Matthews, M Hellard, A Sherker, ... Hepatology 57 (6), 2124-2134, 2013 | 92 | 2013 |
Predicting the short‐term risk of diabetes in HIV‐positive patients: the Data Collection on Adverse Events of Anti‐HIV Drugs (D: A: D) study K Petoumenos, SW Worm, E Fontas, R Weber, S De Wit, M Bruyand, ... African Journal of Reproduction and Gynaecological Endoscopy 15 (2), 2012 | 87 | 2012 |
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons M Rotger, TR Glass, T Junier, J Lundgren, JD Neaton, ES Poloni, ... Clinical infectious diseases 57 (1), 112-121, 2013 | 85 | 2013 |
Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study RL Puls, P Srasuebkul, K Petoumenos, C Boesecke, C Duncombe, ... Clinical infectious diseases 51 (7), 855-864, 2010 | 85 | 2010 |
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction Data Collection on Adverse Events of Anti-HIV Drugs Study Group Clinical infectious diseases 46 (7), 1101-1110, 2008 | 84 | 2008 |